A St. Louis jury rejected a lawsuit against Johnson & Johnson (JNJ) on Friday, the latest of thousands in cases related to the the company’s talc-based products, reports Reuters. The news comes after the New Brunswick, N.J.-based firm lost three back-to-back trials in which the plaintiffs said Johnson & Johnson’s products had contributed to their ovarian and uterine cancer.

A state court jury in Missouri voted 11-1 to deny damages to 55-year-old Nora Daniles from Columbia, Tenn., siding with Johnson & Johnson and talc supplier Imerys Talc. Daniels alleged that she had used J&J Baby Powder for 36 years before being diagnosed with ovarian cancer in 2013.

Plaintiffs: J&J Failed to Properly Warn Users

While more than 2,500 lawsuits related to the talcum powder products are pending in state court in St. Louis, three prior jury verdicts awarded plaintiffs a total of $195 million. In February 2016, J&J was ordered to pay out $72 million to the family of a woman who died from ovarian cancer after using the firm’s products for years for feminine hygiene. In May, the court returned $55 million to a woman with ovarian cancer who said the talc-powder products were directly responsible for her illness. Later in October, J&J was made to pay $67.5 million.

Plaintiffs have accused the consumer goods leader of failing to warn customers about talc’s ability to increase the risk of ovarian cancer. In response, J&J says it acted properly in developing and marketing the products, and that there is insufficient scientific evidence for the claims against talcum powder.

Daniels’ lawyer, Ted Meadows, expressed his disappointment in the verdict: “We continue to maintain that the association between genital talc usage and ovarian cancer remains an issue of public health and demands that consumer be warned of the specific risks,” stated Meadows. (See also: Behind Johnson & Johnson's 91.5% Rise in 10 Years.)

Want to learn how to invest?

Get a free 10 week email series that will teach you how to start investing.

Delivered twice a week, straight to your inbox.